The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

Leveraging Commercial Data Infrastructure in Clinical Drug Development is the greatest connectivity we can have in the ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...

The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological ...

The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from ...

However, it's possible that other drugmakers could be more interested in teaming up with Recursion with the FDA promoting the ...